Lisa Henske, M.D. Named Senior Member at Fox Chase Cancer Center
PHILADELPHIA (Nov. 15, 2006) — Fox Chase Cancer Center has promoted Lisa Henske, MD, to senior member of the divisions of medical science and population science, where she holds dual appointments. A medical oncologist, she became an attending physician in the medical science division's department of medical oncology in 1996 and also conducts research in the population science division's human genetics program. Her clinical and research interests include tuberous sclerosis, cancer genetics and renal-cell carcinoma.
Henske is internationally recognized for her research on tuberous sclerosis, a rare genetic disease resulting in seizures, mental retardation and tumors of multiple organs. Her research on proteins involved in this disease is highly relevant to the process of human cancer development and therapy.
"Lisa's investigations are yielding important new information that will change the way that we think about tuberous sclerosis in particular, and cancer in general," said Louis M. Weiner, MD, chairman of the department of medical oncology. "Lisa's scientific accomplishments have not come at the expense of superb institutional citizenship. She willingly serves on numerous important committees at the institution and has taken an active role in mentoring young researchers, medical residents and medical students. She is truly a wonderful asset to Fox Chase."
Henske earned her M.D. at Harvard Medical School in 1985. She completed both her residency in internal medicine and clinical and research fellowship in hematology-oncology at Massachusetts General Hospital.
Henske is board-certified in internal medicine, medical oncology and hematology. She belongs to the American Society of Clinical Investigation, a national honor society for physician-scientists. Henske also serves on the board of directors and scientific advisory board of two medical foundations.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy6 Moore at 215-728-2700.